Question-and-Answer Session
[Operator Instructions]. Your first question comes from the line of Salveen Kochnover with Collins Stewart. Please proceed.
Salveen Kochnover - Collins Stewart Llc
Thanks for taking my questions. Could you let us know if there is any more EAP or open label extension patients that remain to be switched over to commercial patients at this point?
Stephen Aselage - Senior Vice President, Global Commercial Development
EAP, there are no additional patients that we are aware of, as far as the extension study; I believe the last of the extension study patients won't finish their two years until next month. So, there are very few left... there is probably one or two left on the extension study.
Salveen Kochnover - Collins Stewart Llc
I think at the end of prospects although you provided guidance for third quarter Kuvan sales were slight uptick to the second quarter. How should we think about fourth quarter Kuvan sales and then potentially '09 going forward just given the impact of the marketing initiative?
Stephen Aselage - Senior Vice President, Global Commercial Development
Yes, we're not in a position yet we are ready to give any type of guidance for 2009. But, as I said the referral rate has continued to be about the same as it was through the summer. So I think you can anticipate Q4 to have a slight uptick from Q3, just as Q3 was a slight uptick from Q2. JJ, Jeff just mentioned in the call previously, we are plan on finishing within the guidance for 2008 we are tracking towards the low end of that guidance.
Salveen Kochnover - Collins Stewart Llc
And then in terms of Naglazyme ex-U.S. in '09 apart from Brazil, Eastern Europe and Middle East, are there any additional geographic launches into other geographic country is expected?
Stephen Aselage - Senior Vice President, Global Commercial Development
That's most of the world, outside Western Europe and the United States. But we are just initiating commercial therapy with patients this month in Australia, which is a good opportunity for us as we anticipate and can't promise but we anticipate commercial patient starting in South Korea next year.
There are number of smaller markets that any one of which is not a huge tick for Naglazyme but cumulative where we have a significant impact on a Naglazyme business.
Salveen Kochnover - Collins Stewart Llc
Okay and how, can you just maybe describe the hedging strategy in place for Naglazyme foreign sales just from the foreign exchange impact?
- To read the full transcript on Seeking Alpha, click here »
